PTYLTD
    • Free Reports
    • Videos
  • Pricing
  • About us
  • Contact us
  • Login | Sign up
PTYLTD

Free Reports

Videos

Pricing

About us

Contact us

  • Home
  • Insights into ASX Stocks
  • By Topic

By Topic

American Tungsten & Antimony (ASX: AT4)

American Tungsten & Antimony (ASX: AT4): Refinery goals finally align with a key technical breakout

Aug 10, 2026
Proactive Equities Team

American Tungsten & Antimony (ASX: AT4) advances its US antimony and tungsten strategy through refinery plans, exploration results and a technical breakout setup, highlighting new project developments and potential growth opportunities.

Power Minerals (ASX: PNN)

Power Minerals (ASX: PNN): Morro do Ferro Results Spark a Technical Breakout

Aug 10, 2026
Proactive Equities Team

Power Minerals is drawing attention after strong Morro do Ferro rare-earth drilling, rising trading activity and a breakout above long-held resistance, while further assays and a maiden resource estimate remain key upcoming catalysts.

Austal (ASX: ABS)

Austal (ASX: ABS): Breaks Downtrend with Defence Contracts in Focus

Aug 17, 2026
Proactive Equities Team

Austal (ASX: ASB) gains investor attention after Hanwha’s proposal for Austal USA, alongside major defence contracts and a technical breakout. The company faces both strategic opportunities and execution risks as its shipbuilding plans evolve.

BlinkLab (ASX: BB1)

BlinkLab (ASX: BB1) Gains Momentum: AI Screening Platform Meets a High-Volume BB1 Breakout

Aug 19, 2026
Proactive Equities Team

BlinkLab (ASX: BB1) is advancing its autism and ADHD assessment technology through clinical studies, FDA validation work, and research partnerships. Recent technical strength reflects growing investor interest, though regulatory and commercial risks remain.

Felix Gold (ASX: FXG)

Felix Gold (ASX: FXG) Surges Past Resistance on High Volume as US Antimony Extraction Momentum Accelerates

Aug 19, 2026
Proactive Equities Team

Felix Gold is advancing Alaskan antimony and gold assets, with potential US$18 million DOE pilot-processing funding driving investor interest. The non-dilutive funding could support domestic antimony supply, though project execution, permitting and financing risks remain.

Neuren Pharmaceuticals (ASX: NEU)

Has Neuren Pharmaceuticals' (NEU) share price bottomed out?

Mar 1, 2026
Proactive Equities Team

If you bought Neuren Pharmaceuticals (ASX: NEU) near its peak, the recent volatility has been uncomfortable. Despite having its first approved drug for a rare paediatric disorder, growing royalty income and a promising pipeline, the share price has repeatedly rallied and retraced over the past two years. The key question now is whether NEU has already formed a durable bottom — or if another leg down could still test investor conviction.

...

 

Proactive Equities

At Proactive Equities, we combine deep market expertise with rigorous analysis to deliver stock recommendations you can trust. Our team of seasoned analysts continuously monitor global markets, economic trends, and company fundamentals to identify high-potential investment and trade opportunities.

Company

Home
Pricing
Contact Us
About Us

Resources

ASX Insights
Investing Basics
Videos

Links

Privacy Policy
Terms and Conditions
Product Disclosure Statement

Proactive Equities Pty Ltd (ACN: 687 232 471) is a Corporate Authorised Representative (AFSR No. 001318293) of Australia National Investment Group Pty Ltd (ABN: 40 636 343 630), which holds an Australian Financial Services Licence (AFSL no. 522028). The information on this website is general information only and does not constitute personal financial advice. We have not taken the individual circumstances, financial objectives or needs of any investor into account when preparing this information. Investors should consider their circumstances and the relevant PDS for any investment and obtain professional financial and tax advice before making any investment decision. The information on this website is not a recommendation to make any investment or to adopt any particular investment strategy. You should make your own professional assessment of the suitability of this information, relying on your own inquiries. Investments in securities are subject to investment risk. Investment value may go down as wellas up, and investors may not get back the full amount originally invested. Risks include: the investment objective may not be achieved, share market and other market risk, liquidity risk, and currency risk with international investments. Any past performance shown is not an indication of future performance. Commission and other costs charged by executing broker are not considered when calculating past performance. To the extent permitted by law Proactive Equities Pty Ltd accepts no liability for any errors or omissions in, or loss from reliance on the information in this website.

1...151617...49
Page 16 of 49